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Abstract 
When the cell surface molecule, Human EGF Receptor (HER2), is overexpressed, the 
cell can become cancerous. MDA-MB-453 is an established breast cancer cell line made 
cancerous by HER2 overexpression. This mutation that causes HER2 overexpression affects the 
cell signaling pathway of phosphoinositide 3-kinase (PI3K), Akt, MDM2, and p53. We predicted 
that PI3K would be inhibited with the compound, LY294002, sending signals for Akt and MDM2 
to be deactivated in MDA-MB-453 cells. Deactivated MDM2 signals for p53 to be activated. 
P53 is a tumor suppressor protein that exists in low quantities in normal cells, but when damage 
occurs, p53 expression rises. Its function is to recognize mutations, regulate cell proliferation, 
and induce apoptosis when genetic material is mutated (Ng, Khoo, Heng et al., 2011). The 
effects of PI3K inhibition were determined through an XTT assay, which indicates cell density, 
and a Western blot, to determine the presence of activated p53. The results of the research 
showed that after exposure to PI3K inhibitor, LY294002, cell proliferation did decrease and 
acetylated p53 was present, indicating apoptosis as the cause of death. 
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Introduction 
 The master regulator protein, p53, has an unmatched significance pertaining to the 
survival or death of a cell. Active p53 can direct a cell to repair mutated DNA, arrest the cell 
cycle, block angiogenesis (blood vessel formation), or induce apoptosis (cell suicide) (Wu, 
Bayle, Olson et al., 1993). It responds to internal and external conditions that have the potential 
to harm the cell or the entire organism by altering DNA. These harmful conditions include: lack 
of nucleotides, UV radiation, ionizing radiation, oncogene signaling, hypoxia, and blockage of 
transcription (Fig. 1). Each of the responses are ways that p53 prevents genetic mutations from 
harming the cell and organism (Menendez, Inga, Resnick, 2006). No matter the type of cell, the 
general activity of p53 is to regulate cell proliferation and manage mutated DNA. In its off or 
“inactive” state, p53 is unable to perform any of the functions previously listed that regulate the 
cell’s life. It is important for p53 to be in its active form when there are deleterious mutations, 
but cancer cells can often affect this pathway, consequently keeping p53 in its inactive form 
(Harris, 1996). Continually inactive p53, when it is needed in the active form to forestall tumor 
growth, can end in tumor progression and possible death of the organism. The significance of 
p53 drove the formation of this research. Beginning with p53 and moving upstream in the cell 
signaling pathway, there are molecules, MDM2, Akt, and PI3K. PI3K is a common target of 
inhibition in cell signaling research because it has many known and available inhibitors. If 
upstream molecules of p53 were altered, then it was expected that the functioning of p53 should 
be altered too, and consequently as the functioning of p53 is altered, the survival or apoptosis of 
a cell should also be changed. 
The cell cycle contains different phases for different functions of cell growth and 
replication. Phases G1, S, G2 , and M are the active phases of division, and cytokinesis is the 
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process of the cell splitting into separate cells. Within these phases there are three checkpoints 
that are responsible for examining for mutations (Fig. 2). Each phase contributes its own portion 
of the growth of daughter cells. G1 is the first phase to occur once the cell is triggered to divide. 
In this phase, there is a large amount of growth that occurs inside of the cell; the cell increases in 
size as it produces more mRNA and proteins required for phases later on in the division process. 
The following phase, S, is responsible for replicating the cell’s DNA. G2 is the last step of 
interphase before entering mitosis. It is responsible for more growth of the cell and the proteins 
that are needed during mitosis. Mitosis is the division of the nucleus nearing the end of cell 
division, and its own sub-divisions include: prophase, metaphase, anaphase, telophase. Each 
phase of mitosis is an active part of evenly splitting the nuclear material prepared by interphase 
into the daughter cells.  
Cellular division requires the work of many individual processes to be carried out while 
also working together. There are many events that must occur without error in order to produce 
viable daughter cells, thus, creating the need for checkpoints that monitor the accuracy of cellular 
division processes. Within each phase of the cell cycle, there is a checkpoint that monitors the 
processes for any errors that may have occurred (Fig. 2). If a harmful mutation is detected in S 
phase, the cycle is halted, and the mutation is either fixed and permitted to continue to the next 
phase, or the cell is sent into G0, a resting phase that prevents the division and spread of mutated 
cells. Checkpoints are highly important to the production of properly replicated daughter cells 
(Barnum & O’Connell, 2014). New cells may not be viable or could become cancerous if 
harmful genetic mutations are present. Either of these conditions has the potential to affect the 
organism as a whole if not contained at the original site of mutation.  
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When cancer cells develop there is a mutation in the genetic code that results in abnormal 
growth and function of the cells, including the functioning of checkpoints. One distinct feature of 
cancer cells is their inability to detect growth-inhibitory signals (Harris, 1996). This means that 
the cells are able to pass through all of the checkpoints in the cell cycle that detect mutations, 
giving them the power to proliferate exponentially, assuming that there are available nutrients to 
sustain them. Along with the inability to recognize growth-inhibitory signals and halt the cell 
cycle, cancer cells are unable to recognize contact inhibition signals (Harris, 1996). Cells 
respond to a variety of signals at a time, but when cells are unable to recognize contact inhibition 
signals, there will be too many cells when cell proliferation should be slowing. When cells lack 
this ability, they tend to overgrow to the point where they form masses and eventually overtake 
the organism by depleting it of resources. 
Cell signaling is the method of communication for cells. If drawn out it forms a complex 
web of interactions (Fig. 3). Many molecules can signal to multiple other molecules, adding to 
the complexity of the web. Specifically, for this research, the signaling pathway of 
phosphatidylinositol 3-kinase (PI3K), Akt, MDM2, and p53 was targeted (Fig. 3) (ErbB/HER 
Signaling, 2011). P53 is negatively controlled by this pathway, meaning that when PI3K, Akt, 
and MDM2 are inactive, then p53 is active, and reversely, when PI3K, Akt, MDM2 are active, 
then p53 is inactive. Since p53 is negatively controlled by this pathway, it is in an active or 
inactive state opposite to the activation state of PI3K, Akt, and MDM2. Under specific cellular 
conditions PI3K will send an inhibitory signal to Akt, causing it to be inactive. Akt is then 
responsible for sending an inhibitory signal to MDM2, causing it to be inactive as well 
(ErbB/HER Signaling, 2011).When MDM2 is inactive and not interacting with ARF (binds to 
guanosine triphosphate or guanosine diphosphate), MDM2 then binds to p53, allowing it to be 
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active (Fig. 4). The inactivity of MDM2 prevents inhibitory signals from being sent to p53, 
allowing p53 to function freely (Li, Luo, Brooks et al., 2002). This pathway leading to the 
activation of p53 plays a role in cell cycle by controlling if the cell can proliferate or if it will be 
sent into apoptosis. Cells also have other ways of preventing mutated DNA from being passed 
along to new generations. 
Tumor suppressor genes are another tool used by cells that protect from cancer-causing 
genetic mutations by regulating gene expression. When tumor suppressors are active, they can 
stop the formation of tumors and proliferation of cancer cells. There are many different tumor 
suppressor genes, one being TP53, which codes for protein p53 (Harris, 1996). The activity of 
the p53 pathway can be altered by human intervention. Activity of PI3K can be targeted and 
inhibited with a synthetic compound called LY294002 (Jiang, Fan, Zhou et al., 2010). By 
inhibiting PI3K the signaling sent downstream to Akt and MDM2 will result in activated p53. 
The LY294002 compound is a competitive inhibitor of adenosine triphosphate (ATP), binding 
by interfering with where the ribose of ATP would typically bind to PI3K (Walker, Pacold, 
Perisic et al., 2000). The structure of LY294002 can be seen in Fig. 5. It is a reversible inhibitor, 
meaning that it can be removed, and PI3K can return to its active state (Walker, Pacold, Perisic et 
al., 2000). Alteration of this pathway can be detrimental if the proteins cannot alternate between 
active and inactive states depending on environmental conditions and signaling. A factor such as 
UV radiation should signal for p53 activation to manage the mutated DNA, but if the p53 
pathway is consistently inactive, there will be nothing preventing the cell with damaged DNA 
from replicating and passing along mutated DNA.  
Each type of cancer has its own unique characteristics, and scientists have isolated cell 
lines from many patient biopsy and surgical samples. While they may be from the same tissue 
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(breast, for example), different isolated cell lines exhibit different genetic mutations, 
morphological findings and growth patterns. Breast cancer has been studied using various 
isolated cell lines, each with its own cause as to why it has become cancerous. One breast cancer 
cell line is called MDA-MB-453 (Fig. 6). It is a metastatic carcinoma that was derived from a 
pericardial effusion metastatic site of a 48-year-old Caucasian female (MDA-MB-453, 2018). 
These cells overexpressed fibroblast growth factor receptors (FGF receptors) and have mutant 
cadherin 1 (CDH1 gene) and PIK3CA. PIK3CA is a gene that provides instruction for making a 
subunit that controls the action of PI3K (PIK3CA gene, 2018). MDA-MB-453 cells have an 
overexpression of the cell-surface molecule human EGF receptor 2 (HER2) which plays a role 
giving them their cancerous characteristics.  
In this project, we asked if PI3K would be inhibited by LY294002 in MDA-MB-453 cells 
and if the change in downstream signals would cause p53 to alter cell proliferation or apoptosis 
of the cell. We expected that, if LY294002 was added, p53 should be activated and, therefore, 
apoptosis should occur. As the concentration of LY294002 increased, more p53 should be 
activated which would result in more apoptosis. 
Methods 
Cell line MDA-MB-453 (American Type Culture Collection, Manassas, VA) was 
cultured using Dulbecco’s Modified Eagle Medium (Sigma-Aldrich, St. Louis, MO), including 
10% fetal bovine serum, 4mM glutamine, 100 IU/ml penicillin, 50 μg/mL streptomycin, and 1 
mM sodium pyruvate. The cells were kept in a 5% CO2 water-jacketed incubator (model 
SCO6WE, Shel Lab, Cornelius, OR) at 37C. The cells were replated as needed (indicated by 
change of medium color and examining cells under a microscope).  
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XTT Cell Proliferation Assay 
Optimum cell density was determined before the XTT cell proliferation assay could be 
performed in order to know the best cell density to use. Too little or too many cells would result 
in insufficient ability to collect data. Serial dilutions of cells in complete media from 1x106 to 
1x103 cells per mL, were prepared. In a 96-well microtiter plate (Becton Dickinson Labware, 
Franklin Lakes, NJ), 100 μL of the cell dilutions and a control of complete media alone were 
plated in triplicate, for a total of 15 wells used (These plates are sterile and one-time use only) 
(Fig. 7). The plate was placed in the incubator at 37C for 48 h to further culture the cells in the 
plate. At the 48-h mark, activated-XTT Solution  (2,3-Bis-(2-methoxy-4-nitro-5-sulfophenyl)-
2H-tetrazolium-5-carboxanilide salt) from ATCC was prepared. The XTT reagent and the 
activation reagent were first defrosted in a 37C water bath, and then 0.1 mL of activation reagent 
was added for every 5.0 mL of XTT reagent, which is enough for a full 96-well assay. Each well 
received 50 μL of the activated-XTT solution and was then placed back into the incubator for 
three h. The absorbance of the wells containing the cells and the blank control were determined 
at 450 nm and 630 nm using a BioTek MicroQuant microplate spectrophotometer (BioTek, 
Winooski, VT) to measure the amount of metabolic activity occurring. A wavelength of 450 nm 
was used as a specific filter, and 630 nm was used as a non-specific filter according to the ATCC 
protocol for XTT cell proliferation assay. The average absorbance was determined for both 
filters and the blank. In order to find the specific absorbance, the equation used was:  
 
Specific Absorbance = A450 nm (Test) – A450 nm (Blank) – A630 nm (Test) equation 1. 
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The results were assessed by plotting the absorbance against the number of cells per mL. The 
optimized number of cells for the XTT assay was located within the linear portion of the graph; 
it was determined to be between 104  and 105 cells per well (Fig. 8).   
The cell density used for the analysis of the inhibitor compound, LY294002, was 5x104 
cells per well. The cells were plated in a 6x3 pattern in a 96-well plate, done in triplicate. In 
addition to the cells, a column was plated with complete media alone. Each well contained 100 
μL of solution, either cell dilution or complete media. The three plates were labeled 0 h, 24 h, or 
48 h and placed in the incubator for 24 h to allow the cells to adjust to the new environment.  
After 24 h, each of the plates was treated with 1 μL of the appropriate LY294002 
concentration (Calbiochem Research Biochemicals Burlington, MA) in different concentrations. 
The concentrations included: 0 μM as a no treatment (nothing added), 0 μM for a vehicle (1 μL 
100% vol/vol DMSO from Sigma-Aldrich St. Louis, MO), 10 μM LY294002, 25 μM 
LY294002, 50 μM LY294002 , and 75 μM LY294002. The plate labeled 0 h was immediately 
treated with the activated-XTT solution (50 μL per well). All three of the plates were placed back 
into the incubator. After three hours the absorbance of the 0 h plate was read at 450 nm and 630 
nm. Twenty-four and 48 h later the respective plates were treated with activated-XTT solution, 
and the absorbance was read (Fig. 9). The specific absorbance was calculated the same as for the 
optimal cell density procedure. The results were analyzed by comparing each treatment group of 
a given time, and each time was compared to each other. This procedure was repeated with 
1.5x105 cells per well trials.  
Western Blot 
The next portion of the study included a Western blot that assessed the presence of 
acetylated p53. Cells were first harvested and counted, and the desired dilution was calculated 
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based off of the cell density calculated. In a six-well dish (Corning Inc., Corning NY), 1.0 mL of 
the cell dilution at 1x106 cells/well was added, and 1.0 mL of media was added for a total of 2.0 
mL per well. The plate was placed into the incubator and was left for about 24 h in order to let 
the cells adjust and adhere to the dish. After 24 h, LY294002 was added to four of the six wells. 
Two wells were not treated with any solution, two were treated with a 10 μM concentration of 
LY294002, and two were treated with 25 μM of LY294002. Once the treatment was 
administered, the plate was returned to the incubator for 48 h.  
Cell Harvesting 
RIPA (radioimmunoprecipitation assay) buffer solution was used to harvest proteins from 
treated cells. This solution contained RIPA buffer (10 mM Tris-Cl (pH 8.0), 1 mM EDTA, 1% 
Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 140 mM NaCl, 1 mM PMSF), 10 μg/ml 
aprotinin, 2mM sodium vanadate, and 1:1,000 dilution of protease inhibitor cocktail (Sigma-
Aldrich, St. Louis, MO). Once this buffer was made, a vacuum pump was used to remove the 
media off of the cells. The cells were washed with cold phosphate-buffered saline (PBS) to 
remove any excess media, and this, too, was removed using the vacuum pump. The cells were 
kept on ice during this procedure. After PBS was removed, 200 μL of the RIPA buffer was added 
to each well and let sit for four min. The wells were scraped in order to remove all of the cellular 
material from the plate, and the scraper was changed after each treatment group. Micro-
centrifuge tubes were labeled corresponding to each sample group: NT-A, NT-B (No Treatment), 
10-A, 10-B (10 μM LY294002), 25-A, 25-B (25 μM LY294002), which were then pipetted into 
the respective tube. The tubes were placed, with the hinge facing out, into a cold centrifuge for 
4.5 min at 14,000 rpm. A pellet formed at the bottom of the tube was discarded once the 
supernatant was removed and placed in a separate micro-centrifuge tube with the same labeling.  
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A Bradford protein assay, using reagent materials provided by Bio-Rad (Bio-Rad Protein 
Assay Dye Reagent Concentrate, Bio-Rad Laboratories, Hercules, CA), was then performed to 
assess the amount of protein in the samples. Protein standards were made in order to analyze the 
treatment samples. The standard concentrations consisted of 0, 5, 10, 20, 40, and 80 μg/mL. In a 
96-well dish, standards were plated, including a blank using deionized water. The protein 
samples were plated in duplicate, and each well included 159 μL of sterilized water and 1 μL of 
the protein solution. Bio-Rad dye was then added and mixed thoroughly with the solution. The 
96-well dish was placed into the BioTek plate reader and analyzed at 595 nm using a Bradford 
assay protocol computer program. The data were collected in a spreadsheet and used to calculate 
the values of sample and dye needed to run a Semi-dry SDS-page Western blot (Table 1.).   
The Western blot protocol began by preparing the protein sample and dye mixtures. For 
this procedure, only the samples labeled NT-A, 10-A, and 25-A were used. The amount of 
protein sample required was calculated by dividing 10 by the absorbance collected from the 
Bradford assay for each treatment group of blanked data (Table 1.). Since the Bradford assay 
was done in duplicate, the two values calculated were then averaged to get the total sample 
volume to mix with the dye. The amount of sample buffer needed was calculated by taking the 
total amount of protein sample needed and multiplying it by 0.166. After the calculations were 
done, each solution was made in quadruplicate, by combining the protein sample and dye (Table 
2.). The samples were heated to 95C for four min and then returned to ice while the 7.5% 
polyacrylamide gel (Mini-PROTEAN® TGX™ Precast Polyacrylamide Gels, Bio-Rad, 
Hercules, CA)  and SDS running buffer were assembled in the gel apparatus. The gel was loaded 
with the prepared samples in the order and volumes of: 10 μL protein molecular weight markers 
(Bio-Rad) in lane 1, the complete volume of NT-A sample in lane 2, the complete volume of 10-
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A in lane 3, the complete volume of 25-A in lane 4, and 10 μL of sample buffer in lane 5. This 
layout was repeated in lanes 6-10, and the entire layout was done in duplicate for a total of two 
gels run at the same time (Table 3.). A constant voltage of 200V and freely varying current were 
sent through the gel to move the samples down through the gel. The gel ran for about 30 min and 
was monitored to make sure the samples did not travel out of the gel. After the samples traveled 
through the gel, both gels were removed from the buffer solution and the plastic covering and 
placed into a bucket of the buffer. Two sheets of PDF membrane and four sheets of blotting 
paper were cut into portions that matched the size of the gel. The blotting papers were wetted in 
a bucket of buffer and placed on the semi-dry transfer unit (TE70XP, Hoefer, Inc., Holliston, 
MA). It was gently rolled to remove the presence of any air bubbles. The gel was placed on top 
of the paper and again rolled. PVDF membrane (Millipore, Burlington, MA) was placed on top 
of the gel and rolled, and, finally, another sheet of paper was placed on top of the membrane and 
rolled. A constant current of 360 mA was run for electrophoresis, and then varying voltage was 
run in order to get transfer to the membrane.  
Both membranes were cut in half between lanes 5 and 6, and all four pieces were washed 
by rocking in 1xPBS for five min according to the LI-COR Odyssey protocol (LI-COR 
Biosciences, Lincoln, NE). Then, using the Odyssey blocking buffer, the membranes were 
blocked at room temperature for one h and then decanted. Dilutions of the primary antibody and 
0.1-0.2% of Tween 20 were made. Anti-actin antibody from a mouse (Sigma-Aldrich, St. Louis, 
MO) was prepared at a 1:20,000 dilution, and p53 antibody derived from a rabbit (Cell Signaling 
Technologies, Danvers, MA) was prepared at dilutions 1:250, 1:500, and 1:1000. Separate 
membranes were incubated overnight with different antibody solutions with gentle rocking in a 
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cold box at 4C. The membranes were then washed four times for five min each in PBS plus 0.1% 
Tween 20 while gently rocking. 
IRDye secondary antibody (LI-COR) directed to the primary rabbit or mouse antibody 
was then diluted (1:20,000) in Odyssey blocking buffer plus 0.1-0.2% Tween 20 and incubated 
at room temperature. The membranes were then washed as previously (four times for five min 
each in a generous amount of PBS plus 0.1% Tween 20 with gentle rocking) and were also 
protected from light. Using 1xPBS the membranes were rinsed, and finally scanned on an 
Odyssey Fc Imaging System (LI-COR Biosciences, Lincoln, NE).  
Results 
The optimization assay using XTT showed the best cell density to use per well. The 
optimal density was within the linear portion in the plot. With the data collected from the MDA-
MB-453, the optimal cell density showed to be anywhere starting from 1x104-1x105 cells per 
well (Fig. 8). 
During the first round of adding the LY294002, 5x104 cells per well were used. In the 
second attempt, 1.5x105 cells per well were used. After 48 h of treatment with LY294002, the 
most variability among the different treatment concentrations occurred. At this time, the wells 
that received no treatment had the highest absorbance of XTT, and the 75 μM concentration of 
LY294002 had the lowest absorbance. As the concentration of the compound increased, 
absorbance decreased (Fig. 9). 
Based on the results from the protein assay, the numbers from the standards and the A 
samples were used to calculate the amount of sample and dye needed for the SDS PAGE 
procedure. For NT-A, 27.1 μL of sample and 4.5 μL of dye were combined. Sample 10-A 
 12 
required 29.3 μL of sample and 4.9 μL of dye to be combined. Sample 25-A data required 27.8 
μL of sample and 4.6 μL of dye to be combined (Fig. 10). 
The Western blot showed the presence of actin and p53. In Fig. 11 the Western blot is 
depicting actin and shows weight markers in lane 1 and equal loading of samples in lanes 2-4. 
The markers in lane 1 show the weights 75 kDa, 50 kDa, 37 kDa, and 25 kDa beginning from the 
top of the picture moving down. Lanes 2 and 3 in experiment 2 showed equal loading while lane 
3 showed that there was less sample loaded. Experiment 1 showed that there was equal loading 
in each of the lanes 2-4. Actin has a molecular weight of 42 kDa, and it was seen in lanes 2-4 as 
the dark bands in experiment 2 and as the light bands in experiment 1.  
The portion of the Western blot that tested for active p53 in 1:500 dilution at 700/800 nm 
displayed a light band at the correct position of p53. It showed the darkest band in lane 4, where 
cells were treated with 25μM LY294002 compound. The band of acetylated p53 is light but 
present in the image (Fig. 12).  
Discussion 
 As the concentration of the PI3K inhibitory molecule, LY294002, increased, less cell 
proliferation occurred. The most distinction between the treatment groups was seen after 48 h of 
treatment with the compound (Fig. 12). The Western Blot results using the anti-p53 antibody 
exhibited a small amount of acetylated p53 in the samples. Acetylated p53 is an indicator that 
p53 was activated (Reed & Quelle, 2015). When PI3K was inactivated, p53 was activated. The 
more distinct band in lane 4 of Fig. 11 correlates with the concept that if more PI3K was 
inactivated, the more p53 was activated; more activated/acetylated p53 resulted in a thicker band 
in the Western Blot. This increase in acetylated p53 suggests that the cause of cell death was 
apoptosis.  
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P53 controls the fate of mutated genetic information. Apoptosis is a common outcome of 
p53 activation when there is a mutation in the DNA. Since the MDA-MB-453 cells had mutated 
DNA and p53 was activated by the inhibition of PI3K, it suggests p53 recognized the mutated 
DNA and sent the cells into apoptosis. While our experimentation did not test the actual cause of 
the halt in cell proliferation, the evidence of acetylated p53 suggests the mechanism that p53 sent 
the cells into apoptosis.  
The future of this line of study could include testing the cause of cell death to determine 
whether p53 was responsible for the halt of cell proliferation. Our study is beneficial because it 
shows that when PI3K was inhibited by LY294002, the cell proliferation decreased. However, 
the compound LY294002 cannot be used clinically because it targets and inhibits all PI3K classes 
and other kinases. Therefore, some cellular functions are inhibited when they would be needed. 
While LY294002 cannot be used clinically, current research is focused on the structure of PI3K 
and finding an inhibitor that can target specific PI3Ks (Hayat & Hayat, 2004). Further study 
could test PI3K inhibitors that are specific to certain regions on PI3K to see if they exhibit similar 
cellular results. The concept of inhibiting all activated PI3K in a living organism would 
negatively impact many cellular molecules and would likely affect the organism’s life and 
health, so further studies on how to only target the cancer cells would be a great step towards 
exploiting PI3K inhibition in a clinical setting.  
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Figure 2. The cell cycle and checkpoint descriptions (Weinberg, 2007). 
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Figure 3. Cell signaling pathway including PI3K, Akt, MDM2, and p53 indicated by the circled 
area located in the center of the image (ErbB/HER Signaling, 2011).  
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Table 1. Bradford assay results showed the absorbance for each experimental group. The assay 
indicated the amount of protein present in each sample, which was used to calculate the 
concentrations used in Western blot assay.   
 
 
 
Plate: protein assay 11-8 Date Created: 
11/8/2018 2:37:02 PM        
Raw Absorbance Data         
0.44  NT-A NT-B 10-A 10-B 25-A 25-B 
0.514  0.843 0.711 0.834 0.923 0.83 0.743 
0.635  0.78 0.899 0.741 0.708 0.774 0.592 
0.859        
1.401        
1.958        
Blanked Absorbance Data        
0  NT-A NT-B 10-A 10-B 25-A 25-B 
0.074  0.403 0.271 0.394 0.483 0.39 0.303 
0.195  0.34 0.459 0.301 0.268 0.334 0.152 
0.419        
0.961        
1.518        
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Table 2. Amount of protein sample and dye combined for semi-dry SDS PAGE electrophoresis. 
 
LY294002 Sample 
NT-A 10-A 25-A 
Protein sample (μL) 27.1 29.3 27.8 
Dye (μL) 4.5 4.9 4.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Format of semi-dry SDS PAGE electrophoresis gel. 
Lane 1 2 3 4 5 6 7 8 9 10 
Sample 
10 μL 
MWM 
NT-
A 
10-
A 
25-
A 
10 μL 
buffer 
10 
MWM 
NT-
A 
10-
A 
25-
A 
10 μL 
buffer 
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